CN115279749A - Shp2抑制剂及其组合物和应用 - Google Patents

Shp2抑制剂及其组合物和应用 Download PDF

Info

Publication number
CN115279749A
CN115279749A CN202180021106.8A CN202180021106A CN115279749A CN 115279749 A CN115279749 A CN 115279749A CN 202180021106 A CN202180021106 A CN 202180021106A CN 115279749 A CN115279749 A CN 115279749A
Authority
CN
China
Prior art keywords
amino
dihydrospiro
indene
prop
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180021106.8A
Other languages
English (en)
Other versions
CN115279749B (zh
Inventor
吴颢
吴文茂
李玲
张展
王丰
袁丁
吴云飞
陈强
韩晗
郭晶
兰宏
丁列明
王家炳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN115279749A publication Critical patent/CN115279749A/zh
Application granted granted Critical
Publication of CN115279749B publication Critical patent/CN115279749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

涉及一种作为含Src同源区2蛋白质酪氨酸磷酸酶2(SHP2)抑制剂的化合物(如式1所示)，及其药物组合物、制备方法，以及其在治疗SHP2介导的疾病中的用途。化合物通过参与调节细胞增殖、凋亡、迁移、新生血管生成等多个过程而发挥作用。

Description

PCT国内申请，说明书已公开。

Claims (48)

  1. PCT国内申请，权利要求书已公开。
CN202180021106.8A 2020-04-30 2021-04-22 Shp2抑制剂及其组合物和应用 Active CN115279749B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088435 2020-04-30
CN2020088435 2020-04-30
CN2020119584 2020-09-30
CNPCT/CN2020/119584 2020-09-30
PCT/CN2021/088871 WO2021218755A1 (zh) 2020-04-30 2021-04-22 Shp2抑制剂及其组合物和应用

Publications (2)

Publication Number Publication Date
CN115279749A true CN115279749A (zh) 2022-11-01
CN115279749B CN115279749B (zh) 2024-05-10

Family

ID=78373311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021106.8A Active CN115279749B (zh) 2020-04-30 2021-04-22 Shp2抑制剂及其组合物和应用

Country Status (2)

Country Link
CN (1) CN115279749B (zh)
WO (1) WO2021218755A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
WO2023282702A1 (ko) 2021-07-09 2023-01-12 주식회사 카나프테라퓨틱스 Shp2 억제제 및 이의 용도
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN115611868B (zh) * 2022-05-09 2024-07-23 山东大学 一种呋喃酰胺类衍生物及其制备方法与应用
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916845A (zh) * 2014-01-17 2016-08-31 诺华股份有限公司 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物
CN109311848A (zh) * 2016-06-07 2019-02-05 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2019118909A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2019183367A1 (en) * 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2020063760A1 (en) * 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916845A (zh) * 2014-01-17 2016-08-31 诺华股份有限公司 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物
CN109311848A (zh) * 2016-06-07 2019-02-05 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2019118909A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
WO2019183367A1 (en) * 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2020063760A1 (en) * 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Also Published As

Publication number Publication date
WO2021218755A1 (zh) 2021-11-04
CN115279749B (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
CN115279749B (zh) Shp2抑制剂及其组合物和应用
CN113365988B (zh) Shp2抑制剂及其应用
WO2021043077A1 (zh) 一种取代吡嗪化合物、其制备方法和用途
JP5820921B2 (ja) １，２−二置換複素環式化合物
CN114846005B (zh) Shp2抑制剂及其应用
CN113316574A (zh) Shp2抑制剂及其应用
CN115515947B (zh) Shp2抑制剂及其组合物和应用
WO2020182018A1 (zh) 氮杂环化合物、其制备方法及用途
US20160016907A1 (en) Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
CN115594666B (zh) 一种磷酸酶降解剂的合成和应用
CN111171049A (zh) 酪氨酸激酶抑制剂及其用途
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
WO2022272106A1 (en) Cdk2 inhibitors and methods of using the same
CN113173924B (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
JP2020506877A (ja) Ｓｇｋ活性を調節するための化合物及び医薬組成物、並びにその方法
US9988381B2 (en) Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof
CN110407854B (zh) 新的四环化合物
WO2021227904A1 (zh) 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
US20240116917A1 (en) Iso-citrate dehydrogenase (idh) inhibitor
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2022089219A1 (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
CN111315746B (zh) 色氨酸羟化酶抑制剂和包括该抑制剂的药物组合物
JP2021535924A (ja) 新規なチアゾール誘導体及びその薬学的に許容される塩
CN117730083A (zh) 用作map4k1抑制剂的嘧啶化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant